Aditxt Shares Up After Acquisition Target Appili Files Funding Plans

, MT Newswires -  2:46 PM ET 3/18/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

02:46 PM EDT, 03/18/2025 (MT Newswires) -- Aditxt ( ADTX ) shares were up over 57% in recent Tuesday trading after its acquisition target, Appili Therapeutics, submitted four new federal funding proposals totaling $117.5 million.

The largest funding proposal seeks $46.3 million to develop a vaccine against invasive fungal infections from the National Institute of Allergy and Infectious Diseases, Appili said.

Aditxt ( ADTX ) subsidiary, Adivir, is in the process of acquiring Appili, with the transaction expected to close in Q1, the company said.

Trading volume stood at over 87 million shares against a daily average of about 376,000.

Price: 6.90, Change: +2.53, Percent Change: +57.89

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.